Helixmith

EQS-News: Viromed Medical AG reaches important milestone – agreement with CORIUS Group for exclusive use of Plasma Care® by Viromed with significant growth potential

Retrieved on: 
Friday, May 3, 2024
Plasma, EUR, Patient, Helixmith, Dermatology, Growth, Pharmaceutical industry

Pinneberg, 22 April 2024 – Viromed Medical AG (ISIN: DE000A3MQR65) has concluded an agreement with CORIUS Group for the exclusive use of the pioneering cold plasma therapy with Plasma Care® by Viromed for their 1,250,000 patients and is establishing Plasma Care® by Viromed as the benchmark in Germany.

Key Points: 
  • Pinneberg, 22 April 2024 – Viromed Medical AG (ISIN: DE000A3MQR65) has concluded an agreement with CORIUS Group for the exclusive use of the pioneering cold plasma therapy with Plasma Care® by Viromed for their 1,250,000 patients and is establishing Plasma Care® by Viromed as the benchmark in Germany.
  • Viromed Medical AG believes that the use of Plasma Care® by Viromed by the CORIUS Group will have a signal effect for wound treatment in Germany, further accelerating the spread of innovative cold plasma therapy.
  • Uwe Perbandt, CEO of Viromed Medical AG: ”This agreement is a real milestone for the economic success of our company.
  • Through the exclusive use of our pioneering cold plasma therapy in the facilities of the CORIUS Group with its 1,250,000 patients, Plasma Care® by Viromed will play a key role in innovative wound care.

Helixmith to Present New ALS-Focused Development Program at Upcoming Conferences

Retrieved on: 
Tuesday, October 4, 2022
SMN, Diaphragm, Muscle, Trial of the century, UMN, Research, Clinical trial, AAV, Muscle atrophy, Macrophage, NMJ, Neuromuscular junction, HGF, Therapy, Hepatocyte growth factor, Respiration, Mesa, Conference, Patient, Cell, Helixmith, DNA, ALS, Motor neuron, Pharmaceutical industry, Medical imaging, Vaccine, DART

Its receptor, c-Met, is present in all major cell types important in ALS, including motor neurons, inflammatory macrophages, and skeletal muscles (such as the diaphragm and accessory muscles of respiration).

Key Points: 
  • Its receptor, c-Met, is present in all major cell types important in ALS, including motor neurons, inflammatory macrophages, and skeletal muscles (such as the diaphragm and accessory muscles of respiration).
  • Helixmith is hence using an HGF that binds to key cell types involved in ALS pathogenesis, including motor neurons, macrophages, and skeletal muscles.
  • Helixmith recently completed a Phase 1 and a Phase 2a clinical trial using Plasmid DNA-encoding HGF modality (Engensis or VM202).
  • To achieve their goal to complete clinical studies with two other modalities, Helixmith will need to raise additional capital.

Global Peripheral Neuropathy Clinical Trial Pipeline Research Report 2021: Phase 3, Phase 2, Phase 1, Preclinical Research, and Discovery Stage - ResearchAndMarkets.com

Retrieved on: 
Thursday, July 15, 2021
Health, Clinical trials, Health sciences, Health, Drug discovery, Life sciences, Clinical research, Pharmaceutical industry, Peripheral neuropathy, Clinical trial, Helixmith, Diabetic neuropathy

The "Global Peripheral Neuropathy Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Peripheral Neuropathy Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • Peripheral Neuropathy Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Peripheral Neuropathy market.
  • It covers emerging therapies for Peripheral Neuropathy in active clinical development stages including early and late stage clinical trials.
  • The report provides Peripheral Neuropathy pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.

Global Diabetic Foot Ulcers Clinical Trials Review, H1 2021 Research Report - ResearchAndMarkets.com

Retrieved on: 
Wednesday, July 7, 2021
Health, Clinical trials, Health, Clinical research, Life sciences, Diabetes, Foot diseases, Pharmaceutical industry, Drug discovery, Clinical trial, Diabetic foot ulcer, Diabetic foot, Helixmith

The "Diabetic Foot Ulcers - Global Clinical Trials Review, H1, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Diabetic Foot Ulcers - Global Clinical Trials Review, H1, 2021" clinical trials has been added to ResearchAndMarkets.com's offering.
  • This report presents top line data relating to the clinical trials on Diabetic Foot Ulcers.
  • The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type.
  • Report also provides prominent drugs for in-progress trials (based on number of ongoing trials).

Hepatocyte Growth Factor Pipeline Report, H2 2020 Edition - ResearchAndMarkets.com

Retrieved on: 
Monday, April 26, 2021
Health, Pharmaceutical, Branches of biology, Biology, Cytokines, Hepatocyte growth factor, HGF, Growth factor, Wound healing, Myogenesis, c-Met inhibitor, Helixmith

b'The "Hepatocyte Growth Factor - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\n\'Hepatocyte Growth Factor - Pipeline Review, H2 2020\'; Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 15 molecules.\nHepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor.

Key Points: 
  • b'The "Hepatocyte Growth Factor - Pipeline Review, H2 2020" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\n\'Hepatocyte Growth Factor - Pipeline Review, H2 2020\'; Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) pipeline Target constitutes close to 15 molecules.\nHepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) - Hepatocyte growth factor (HGF) is a paracrine cellular growth and morphogenic factor secreted by mesenchymal cells and stimulates epithelial cell proliferation, motility, morphogenesis and angiogenesis in various organs via tyrosine phosphorylation of its receptor.
  • It has a major role in embryonic organ development, specifically in myogenesis, in adult organ regeneration and in wound healing.
  • In addition, HGF exerts protective effects on epithelial and non-epithelial organs (including the heart and brain) via anti-apoptotic and anti-inflammatory signals.\nThe report \'Hepatocyte Growth Factor - Pipeline Review, H2 2020\' outlays comprehensive information on the Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.\nIt also reviews key players involved in Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF) targeted therapeutics development with respective active and dormant or discontinued projects.
  • Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 5, 3, 4 and 3 respectively.\nThe report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities\n'

Helixmith Announces First Patient Enrolled in Phase 2 Study of Engensis (VM202) for Amyotrophic Lateral Sclerosis

Retrieved on: 
Wednesday, March 10, 2021
Motor neuron diseases, Helixmith, Life sciences, Rare diseases, Neuroscience, Amyotrophic lateral sclerosis, Branches of biology, Amyotrophy, Charcot disease, Amyotrophic lateral sclerosis research

The purpose of the Engensis ALS study is to evaluate the safety and tolerability of Engensis in 18 ALS patients.

Key Points: 
  • The purpose of the Engensis ALS study is to evaluate the safety and tolerability of Engensis in 18 ALS patients.
  • In addition, Engensis' effect on muscle function and strength will be assessed using the Amyotrophic Lateral Sclerosis Function Rating (ALSFRS-R) and Hand-Held Dynamometry (HHD).
  • If positive data is secured from the current study, Helixmith plans to conduct an expanded Phase 2B trial.
  • Engensis (VM202), the most advanced pipeline candidate, is a plasmid DNA therapy being studied for DPN, diabetic foot ulcers, claudication, amyotrophic lateral sclerosis, coronary artery disease, and Charcot-Marie-Tooth disease.

2021 Global Renal Cell Carcinoma Clinical Trial Pipeline Highlights - ResearchAndMarkets.com

Retrieved on: 
Monday, March 8, 2021
Health, Clinical trials, Health sciences, Health, Kidney cancer, Life sciences, Renal cell carcinoma, Clinical trial, Helixmith, SeaGen

The "Global Renal Cell Carcinoma Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Renal Cell Carcinoma Clinical Trial Pipeline Highlights - 2021" report has been added to ResearchAndMarkets.com's offering.
  • The latest report Renal Cell Carcinoma Pipeline Highlights - 2021, provides the most up-to-date information on key pipeline products in the global Renal Cell Carcinoma market.
  • It covers emerging therapies for Renal Cell Carcinoma in active clinical development stages including early and late stage clinical trials.
  • The report provides Renal Cell Carcinoma pipeline products by clinical trial stages including both early and late stage development - phase 3 clinical trials, phase 2 clinical trials, phase 1 clinical trials, preclinical research, and discovery stage.